Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer

Data regarding nivolumab as second line treatment in advanced non-small cell lung cancer (NSCLC) are based on selected populations and might not reflect daily practice. Investigators aimed at assessing efficacy and safety of nivolumab in a real-life setting and determining a subtype of NSCLC patients that are more likely to benefit from immunotherapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

NSCLC

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHRU de Brest, Brest, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

advanced NSCLC (stage IIIB-IV)
failure of at least one line of chemotherapy.
age ≥18 years,
initiation of nivolumab between 01/09/2015 and 30/09/2016.

Exclusion criteria

nivolumab initiation after October 2016
prior involvement in an immunotherapy trial
refusal to participate.

Treatment and study plan

Primary outcomes

Nivolumab Objective response rate

Time frame: through study completion, an average of 1 year

Objective response rate evaluated by RECIST 1.1

Sponsors and collaborators

Lead sponsor

University Hospital, Brest

Other

Registry information

Official study title

Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer: a French Observational Multicenter Study of 259 Patients (ABCT-IMMUNOBZH)

Acronym: IMMUNOBZH

Important dates

Study start: 2017
Primary completion: 2017
Study completion: 2017
First posted: Apr 26, 2021
Registry last updated: Apr 26, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed